NEW HAVEN, Connecticut, September 3, 2026, 14:18 EDT — BioXcel shares climbed 8% with trading volumes reaching 143 million ahead of delisting.
- BioXcel stock climbed 8.4% to $0.1160 as of 13:59 EDT.
- Trading volume totaled 143.1 million shares, which is 4.57 times greater than the share count in June.
- Nasdaq intends to halt trading on September 8 ahead of a transition to Pink Limited.
Shares of BioXcel Therapeutics Inc. NASDAQ:BTAI climbed 8.4% on Thursday, with trading volume totaling 143.1 million shares. At 13:59 EDT, the stock was quoted at $0.1160, based on a delayed market quote.
Trading volume reached 4.57 times BioXcel’s share count as of June 30. However, the stock stayed 83.9% lower than its August 27 closing price, according to daily price records. The surge thus reflects a liquidity event centered on a distressed asset.
BTAI price path after the bankruptcy filing
Daily closes in dollars; September 3 is the delayed intraday price.
As of . Sources: ChartExchange and FinancialContent.
The difference is clarified by the capital structure. A new $77.25 million debtor-in-possession facility holds superpriority status and is secured by first-ranking liens. This amount is 21 times higher than the estimated $3.6 million equity value.
The facility includes just $19 million in fresh capital, while the other $58.25 million allows current lenders to convert their claims into the senior facility. This arrangement safeguards ongoing operations and advances lender claims ahead of those of common shareholders.
As of June 30, BioXcel held $28.8 million in assets against $144.3 million in liabilities. Its quarterly filing revealed a stockholders’ deficit of $115.5 million. These numbers do not reflect the impact of the bankruptcy financing.
Claims dwarf the quoted equity value
USD millions. Bars share a common $144.3 million scale; the bid is not a recovery forecast.
Balance-sheet data as of June 30, 2026. Equity value estimate uses the June share count and the 13:59 EDT price. Sources: BioXcel 10-Q, BioXcel 8-K, and Teva.
Teva Pharmaceutical Industries Ltd. NYSE:TEVA proposed an upfront payment of $57.5 million to acquire nearly all assets. Its stalking-horse offer also features potential contingent payments up to $67.5 million. Teva is purchasing assets only, rather than BioXcel’s equity.
BioXcel CEO Vimal Mehta described the process as a “clear framework to pursue a value-maximizing transaction.” His statement included reference to all stakeholders. The company announcement did not guarantee a distribution to shareholders.
The core business provides limited short-term support. Product revenue in the second quarter reached $182,000, compared to an operating loss of $10.2 million. Cash holdings at the end of June were $12.8 million.
The auction continues to offer strategic benefits. IGALMI and its at-home application are linked to a November 14 FDA target action date. Teva executive Evan Lippman stated the deal “strengthens our neuroscience portfolio.”
Nasdaq will halt trading of BTAI at the start of business on September 8. BioXcel has opted not to contest the move. The company anticipates that its shares will move to the Pink Limited Market, where trading volumes could be reduced.
The restructuring clock
Sources: BioXcel 8-K and company release.
The volume amount includes every transaction, counting all instances of resale. It does not indicate that 143 million unique shares changed hands. A high turnover rate may suggest speculation, short covering, or investors closing positions.
The DIP loans have an annual interest rate of 13% along with a 4% exit fee. They are set to mature on January 27, 2027, unless they are repaid earlier through a sale or a default occurs. If fully utilized, yearly interest payments would total over $10 million.
Risks: Estate value could rise if there is a higher auction bid or FDA approval. Common shareholders receive recoveries only after settling senior, administrative, and additional claims. Delisting may also significantly limit trading access.
Thursday’s rise affects the quote but leaves the claim hierarchy unchanged. The results of the auction and the September 8 suspension now outweigh the significance of the day’s percentage change.
